← back to search

Yen‐Chuan Ou

Dongguan University of Technology · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Prostate Cancer Diagnosis and Treatment, Renal cell carcinoma treatment, Prostate Cancer Treatment and Research, and Bladder and Urothelial Cancer Treatments.
h-index
41
citations
6,148
works
377
NIH funding
primary concept
Medicine
email

Recent publications

Comprehensive analysis of prostate cancer life expectancy, loss of life expectancy, and healthcare expenditures: Taiwan national cohort study spanning 2008 to 2019.
2025cited by 1position: contributordoi
Gender disparities in bladder cancer: A population-based study on life expectancy and health spending in Asia.
2025cited by 0position: contributordoi
Robot-assisted radical prostatectomy using hugo RAS system: The pioneer experience in Taiwan and Northeast Asia.
2023cited by 11position: contributordoi
Validation of robotic-assisted ureteroplasty with buccal mucosa graft for stricture at the proximal and middle ureters: the first comparative study.
2022cited by 7position: contributordoi
Diffusive Ki67 and vimentin are associated with worse recurrence-free survival of upper tract urothelial carcinoma: A retrospective cohort study from bench to bedside
Urologic Oncology: Seminars and Original Investigations 2022cited by 5position: contributordoi
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology 2020cited by 492position: middledoi
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
The Lancet 2017cited by 177position: middledoi
Diagnosing the miR-141 prostate cancer biomarker using nucleic acid-functionalized CdSe/ZnS QDs and telomerase
Chemical Science 2014cited by 129position: middledoi
Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
Clinical Cancer Research 2014cited by 56position: middledoi
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand–foot skin reactions
Supportive Care in Cancer 2012cited by 11position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

· 5 papers (2022–2025)Chao Yu Hsu · National Chung Hsing University3 papers (2022–2023)Min Che Tung · National Chung Hsing University3 papers (2022–2023)Wei Chun Weng · National Chung Hsing University3 papers (2022–2023) · 3 papers (2022–2023)Che Hsueh Yang · Houston Methodist3 papers (2022–2023)Chin Heng Lu · Taipei Medical University2 papers (2022–2022)Li Hua Huang · Taipei Medical University2 papers (2022–2023) · 2 papers (2012–2014)Chen‐Li Cheng · Tulane University1 papers (2012–2012)Wen-Ming Chen · Wenzhou Medical University1 papers (2012–2012) · 1 papers (2012–2012)Matthew Squires · Tris Pharma (United States)1 papers (2014–2014) · 1 papers (2012–2012) · 1 papers (2012–2012) · 1 papers (2012–2012)Sarah Beall · National Taiwan University Hospital1 papers (2014–2014)Michael Shi · Hua Medicine (China)1 papers (2014–2014)Yi Hong Li · China Medical University1 papers (2025–2025)Pin-Chun Liu · Tungs' Taichung MetroHarbor Hospital1 papers (2025–2025)